Fractyl Health (NASDAQ:GUTS – Get Free Report) and AnaptysBio (NASDAQ:ANAB – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.
Earnings & Valuation
This table compares Fractyl Health and AnaptysBio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fractyl Health | $90,000.00 | 159.12 | -$140.95 million | ($10.56) | -0.10 |
| AnaptysBio | $234.60 million | 6.21 | -$13.23 million | $5.37 | 9.07 |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Fractyl Health and AnaptysBio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fractyl Health | 1 | 1 | 3 | 0 | 2.40 |
| AnaptysBio | 1 | 3 | 13 | 0 | 2.71 |
Fractyl Health presently has a consensus target price of $50.25, indicating a potential upside of 4,552.78%. AnaptysBio has a consensus target price of $77.79, indicating a potential upside of 59.63%. Given Fractyl Health’s higher probable upside, equities research analysts plainly believe Fractyl Health is more favorable than AnaptysBio.
Volatility and Risk
Fractyl Health has a beta of 2.42, indicating that its stock price is 142% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.
Profitability
This table compares Fractyl Health and AnaptysBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fractyl Health | N/A | -1,362.10% | -84.89% |
| AnaptysBio | 82.37% | 112.00% | 2.20% |
Summary
AnaptysBio beats Fractyl Health on 8 of the 11 factors compared between the two stocks.
About Fractyl Health
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
About AnaptysBio
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
